Recent studies have demonstrated that dysregulated MDH1 is associated with cancer progression, metabolic reprogramming, and therapy resistance in pancreatic cancer (54), breast cancer (55), and lung adenocarcinoma (56). Here, MDH1 is linked to familial pancreatic carcinoma.